Evidence map›Paper›PMID 33276497›Full record

ArticleDiagnostics (Basel, Switzerland)2020

Design and Characterization of a Novel Blood Collection and Transportation Device for Proteomic Applications.

Nathan K Kaiser, Maximillian Steers, Charles M Nichols, Hestia Mellert, Gary A Pestano

Open access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Clinical evaluation of patterned dried plasma spot cards to support quantification of HIV viral load and reflexive genotyping.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Nathan K KaiserBiodesix Inc., 2970 Wilderness Place Suite 100, Boulder, CO 80301, USA.
Maximillian SteersBiodesix Inc., 2970 Wilderness Place Suite 100, Boulder, CO 80301, USA.
Charles M NicholsBiodesix Inc., 2970 Wilderness Place Suite 100, Boulder, CO 80301, USA.ORCID 0000-0001-9398-3410
Hestia MellertBiodesix Inc., 2970 Wilderness Place Suite 100, Boulder, CO 80301, USA.
Gary A PestanoBiodesix Inc., 2970 Wilderness Place Suite 100, Boulder, CO 80301, USA.
Helix Biomedix (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A major hurdle for blood-based proteomic diagnostics is efficient transport of specimens from the collection site to the testing laboratory. Dried blood spots have shown utility for diagnostic applications, specifically those where red blood cell hemolysis and contamination of specimens with hemoglobin is not confounding. Conversely, applications that are sensitive to the presence of the hemoglobin subunits require blood separation, which relies on centrifugation to collect plasma/serum, and then cold-chain custody during shipping. All these factors introduce complexities and potentially increased costs. Here we report on a novel whole blood-collection device (BCD) that efficiently separates the liquid from cellular components, minimizes hemolysis in the plasma fraction, and maintains protein integrity during ambient transport. The simplicity of the design makes the device ideal for field use. Whole blood is acquired through venipuncture and applied to the device with an exact volume pipette. The BCD design was based on lateral-flow principles in which whole blood was applied to a defined area, allowing two minutes for blood absorption into the separation membrane, then closed for shipment. The diagnostic utility of the device was further demonstrated with shipments from multiple sites (n = 33) across the U.S. sent to two different centralized laboratories for analyses using liquid chromatography/mass spectrometry (LC/MS/MS) and matrix assisted laser desorption/ionization-time of flight (MALDI-ToF) commercial assays. Specimens showed high levels of result label concordance for the LC/MS/MS assay (Negative Predictive Value = 98%) and MALDI-ToF assay (100% result concordance). The overall goal of the device is to simplify specimen transport to the laboratory and produce clinical test results equivalent to established collection methods.

Indexed as

blood collection deviceclinical proteomicsdiagnosticsMALDI-ToFMultiple Reaction Monitoring (MRM)

Identifiers

PMID33276497
PMCPMC7761483
OpenAlexW3107104358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.